Voyager vaulted upwards on Pfizer deal news
The value of US gene therapy company Voyager Therapeutics (Nasdaq: VYGR) doubled in Wednesday’s early trading following news of a deal with the world’s largest pharma company.
Through this agreement, Pfizer (NYSE: PFE) may exercise options to license novel capsids generated from Voyager’s RNA-driven TRACER (tropism redirection of AAV by cell-type-specific expression of RNA) screening technology in the development, manufacturing and commercialization of gene therapies, utilizing two undisclosed transgenes to treat certain neurologic and cardiovascular diseases.
"Promise to unlock the fullest potential of gene therapies for a wide array of diseases"Michael Higgins, interim chief executive of Voyager, said: “This transaction highlights the potential of our TRACER platform to identify novel AAV capsids that target desired cells and tissues with greater specificity at lower doses and with fewer off-target risks than conventional AAV serotypes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze